본문 바로가기
KERD
논문KCI 등재

COVID-19: An overview of current scenario

Mudasir Maqbool|Jonaid Ahmad Malik
셀메드 세포교정의약학회 (Cellmed Orthocellular Medicine and Pharmaceutical Association)|2020.08|셀메드 (CELLMED)|제10권 제3호|pp. 21-21|DOI http://dx.doi.org/10.5667/CellMed.2020.0021

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19diagnosisSARS-CoV-2therapies
주제분류의학일반

초록

Over a span of few decades, the world has seen the emergence of new viruses that have posed serious problems to global health .COVID-19 is a major pathogenic threat to the modern world that primarily shoots the respiratory system of human beings. Wuhan which is the capital city of Hubei, China was the first place in the world where first cases of COVID-19 emerged and the scores of cases significantly increased at an immense rate leading to city isolation and establishment of new specially designed hospitals. SARS-CoV had emerged from bats in china (2002) and MERS-CoV from camels transmitted via bats in Middle East (2012) where the previous versions of COVID-19 took place. Infections with SARS-CoV-2 are now widespread, like Nuclear Chain Reaction (NRC). In this review we will discuss the COVID-19 origin, transmission, incubation, diagnosis and therapies available at the present scenario.

Abstract

Over a span of few decades, the world has seen the emergence of new viruses that have posed serious problems to global health .COVID-19 is a major pathogenic threat to the modern world that primarily shoots the respiratory system of human beings. Wuhan which is the capital city of Hubei, China was the first place in the world where first cases of COVID-19 emerged and the scores of cases significantly increased at an immense rate leading to city isolation and establishment of new specially designed hospitals. SARS-CoV had emerged from bats in china (2002) and MERS-CoV from camels transmitted via bats in Middle East (2012) where the previous versions of COVID-19 took place. Infections with SARS-CoV-2 are now widespread, like Nuclear Chain Reaction (NRC). In this review we will discuss the COVID-19 origin, transmission, incubation, diagnosis and therapies available at the present scenario.

참고문헌 (96)

  1. 안대균, "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)", Journal of Microbiology and Biotechnology, 30(3), pp.313~324 (2020), 한국미생물·생명공학회
  2. Al-Tawfiq JA, "Ribavirinand interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus : an observational study", International Journal of Infectious Diseases, 20, pp.42~46 (2014)
  3. Anderson G, "Ebola virus : melatonin asa readily available treatment option", Journal of medical virology, 87(4), pp.537~543 (2015)
  4. André FE, "The future of vaccines, immunisation concepts and practice", Vaccine, 19(17-19), pp.2206~2209 (2001)
  5. Annan A, "Human betacoronavirus 2c EMC", 2012–related viruses in bats, Ghana and Europe, 2013, pp.19(3), 456~
  6. "WORLDOMETERS"[URL]
  7. Backer J, "The incubation period of 2019-nCoV infections among travellers from Wuhan", China. medRxiv, 2020 (2019)
  8. Backer JA, "Incubation period of 2019 novel coronavirus(2019-nCoV)infections among travellers from Wuhan, China, 20–28 January 2020", Eurosurveillance, 25(5), pp.2000062~ (2020)
  9. Bai Y, "Presumed asymptomatic carrier transmission of COVID-19", Jama, 323(14), pp.1406~1407 (2020)
  10. Ben-Nathan D, "Protective effects of melatonin in mice infected with encephalitis viruses", Archives of virology, 140(2), pp.223~230 (1995)
  11. Boga JA, "Beneficial actions of melatonin in the management of viral infections : a new use for this"molecular handyman"", Reviews in medical virology, 22(5), pp.323~338 (2012)
  12. Chan JFW, "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission : a study of a family cluster", The Lancet, 395(10223), pp.514~523 (2020)
  13. Chen L, "Convalescent plasma as a potential therapy for COVID-19", The Lancet infectious diseases, 20(4), pp.398~400 (2020)
  14. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", The Lancet, 395(10223), pp.507~513 (2020)
  15. Chen Y, "A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus", Emerging microbes & infections, 4(1), pp.1~5 (2015)
  16. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", European Journal of Clinical Microbiology and Infectious Diseases, 24(1), pp.44~46 (2005)
  17. Choy M, "Pharmaceutical approval update", Pharmacy and Therapeutics, 41(5), pp.288~ (2016)
  18. Chu C, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59(3), 252~256
  19. Corman VM, "Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat", Journal of virology, 88(19), pp.11297~11303 (2014)
  20. Corman VM, "Detection of 2019 novel coronavirus(2019-nCoV)by real-time RT-PCR", Euro Surveill, 25(3), pp.1560~7917 (2020)
  21. Coutard B, "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade", Antiviral research, 176, pp.104742~ (2020)
  22. da Cunha Pedrosa AM, "Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation", The Journal of Immunology, 184(7), pp.3487~3494 (2010)
  23. De Clercq E, "New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections", Chemistry–An Asian Journal, 14(22), pp.3962~3968 (2019)
  24. Debing Y, "Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon", Antimicrobial agents and chemotherapy, 58(1), pp.267~273 (2014)
  25. Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proceedings of the National Academy of Sciences, 117(17), pp.9490~9496 (2020)
  26. Fehr AR, "Coronaviruses: an overview of their replication and pathogenesis", Coronaviruses, pp.1~23 (2015)
  27. Fung TS, "Human Coronavirus : Host-Pathogen Interaction", Annual review of microbiology, 73, pp.529~557 (2019)
  28. Gao J, "Breakthrough : Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies", Biosci Trends, 14(1), pp.72~73 (2020)
  29. Graham RL, "A decade after SARS : strategies for controlling emerging coronaviruses", Nature Reviews Microbiology, 11(12), pp.836~848 (2013)
  30. Guan W, "Clinical characteristics of 2019 novel coronavirus infection in China", MedRxiv, ~ (2020)
  31. Guarner J, "Three emerging coronaviruses in two decades : the story of SARS, MERS, and now COVID-19", Am J Clin Pathol, 153(4), pp.420~421 (2020)
  32. Hardeland R, "Melatonin and inflammation—Story of a double-edged blade", Journal of pineal research, 65(4), pp.e12525~ (2018)
  33. He Y, "Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies : implication for developing subunit vaccine", Biochemical and biophysical research communications, 324(2), pp.773~781 (2004)
  34. Holshue ML, "First case of 2019 novel coronavirus in the United States", New England Journal of Medicine (2020)
  35. Howlader N, "Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era", Cancer, 123(17), pp.3326~3334 (2017)
  36. Huang C, "Clinical features of patients infected with 2019 novelcoronavirus in Wuhan, China", The Lancet, 395(10223), pp.497~506 (2020)
  37. Huang SH, "Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice", Journal of pineal research, 48(2), pp.109~116 (2010)
  38. Hung IF, "Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A(H1N1)2009 virus infection", Clinical Infectious Diseases, 52(4), pp.447~456 (2011)
  39. Huynh J, "Evidence supporting a zoonotic origin of human coronavirus strain NL63", Journal of virology, 86(23), pp.12816~12825 (2012)
  40. Junaid A, "Ebola Hemorrhagic Shock Syndrome-on-a-Chip", iScience, 23(1), pp.100765~ (2020)
  41. Kan B, "Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms", Journal of virology, 79(18), pp.11892~11900 (2005)
  42. Keyaerts E, "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine", Biochemical and biophysical research communications, 323(1), pp.264~268 (2004)
  43. Ko J-H, "Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience", Antiviral therapy, 23(7), pp.617~622 (2018)
  44. Kono M, "Inhibition of human coronavirus 229E infection in human epithelial lung cells(L132)by chloroquine : involvement of p38 MAPK and ERK", Antiviral research, 77(2), pp.150~152 (2008)
  45. Lau SK, "Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle : implications for the origin of the novel Middle East respiratory syndrome coronavirus", Journal of virology, 87(15), pp.8638~8650 (2013)
  46. Lee PI, "Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV", Journal of Microbiology, Immunology and Infection (2019)
  47. Lei J, "CT Imaging of the 2019 Novel Coronavirus(2019-nCoV)Pneumonia", Radiology, 295(1), pp.31~ (2020)
  48. Lessler J, "Incubation periods of acute respiratory viral infections : a systematic review", The Lancetinfectious diseases, 9(5), pp.291~300 (2009)
  49. Leyssen P, "The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase", Journal of virology, 79(3), pp.1943~1947 (2005)
  50. Li F, "Structure, function, and evolution of coronavirus spike proteins", Annual review of virology, 3, pp.237~261 (2016)
  51. Li J, "Advances in mRNA vaccines for infectious diseases", Frontiers in Immunology, 10, pp.594~ (2019)
  52. Li Q, "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia", N Engl J Med, 382(13), pp.1199~1207 (2020)
  53. Li W, "Bats are natural reservoirs of SARS-like coronaviruses", Science, 310(5748), pp.676~679 (2005)
  54. Ling Y, "MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome", Life sciences, 210, pp.1~8 (2018)
  55. Linton NM, "Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation : a statistical analysis of publicly available case data", Journal of clinical medicine, 9(2), pp.538~ (2020)
  56. Liu K, "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province", Chinese medical journal (2020)
  57. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", The Lancet, 395(10224), pp.565~574 (2020)
  58. Mahase E, "China coronavirus : WHO declares international emergency as death toll exceeds 200", Bmj, 368, pp.m408~ (2020)
  59. Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis", The Journal of infectious diseases, 211(1), pp.80~90 (2015)
  60. Malik YS, "Emerging novel coronavirus(2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments", Veterinary quarterly, 40(1), pp.68~76 (2020)
  61. Meng L, "Coronavirus Disease 2019(COVID-19) : Emerging and Future Challenges for Dental and Oral Medicine", Journal of Dental Research, 99(5), pp.481~487 (2020)
  62. Meyer B, "Serological assays for emerging coronaviruses : challenges and pitfalls", Virus research, 194, pp.175~183 (2014)
  63. Mukherjee P, "Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits", Bioorganic & medicinal chemistry, 16(7), pp.4138~4149 (2008)
  64. Pronker ES, "Risk in vaccine research and development quantified", PloS one, 8(3) (2013)
  65. Que T, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir : a multicentre retrospective matched cohort study, 2003, pp.9(6), 399~406
  66. Reiter RJ, "Melatonin in mitochondria : mitigating clear and present dangers", Physiology, 35(2), pp.86~95 (2020)
  67. Reiter RJ, "Treatment of Ebola and other infectious diseases : melatonin"goes viral"", Melatonin Research, 3(1), pp.43~57 (2020)
  68. Rothan HA, "The epidemiology and pathogenesis of coronavirus disease(COVID-19)outbreak", J Autoimmun, 109(102433), pp.26~ (2020)
  69. Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", New England Journal of Medicine, 382(10), pp.970~971 (2020)
  70. Savarino A, "Effects of chloroquine on viral infections : an old drug against today's diseases", The Lancet infectious diseases, 3(11), pp.722~727 (2003)
  71. Savarino A, "Cassone A New insights into the antiviral effects of chloroquine. edn", The Lancet Infect Dis, 6(2), pp.67~69 (2006)
  72. Shang Y, "Melatonin reduces acute lung injury in endotoxemic rats", Chinese medical journal, 122(12), pp.1388~1393 (2009)
  73. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Science translational medicine, 9(396) (2017)
  74. Shi Z, "A review ofstudies on animal reservoirs of the SARS coronavirus", Virus research, 133(1), pp.74~87 (2008)
  75. Singhal T, "A Review of Coronavirus Disease-2019(COVID-19)", The Indian Journal of Pediatrics, 87(4), pp.281~286 (2020)
  76. So LK, "Development of a standard treatment protocol for severe acute respiratory syndrome", The Lancet, 361(9369), pp.1615~1617 (2003)
  77. Sola I, "Continuous and discontinuous RNA synthesis in coronaviruses", Annual review of virology, 2, pp.265~288 (2015)
  78. Sun CK, "Systemic combined melatonin–mitochondria treatment improves acute respiratory distress syndrome in the rat", Journal of pineal research, 58(2), pp.137~150 (2015)
  79. Van Griensven J, "Evaluation of convalescent plasma for Ebola virus disease in Guinea", New England Journal of Medicine, 374(1), pp.33~42 (2016)
  80. Varia M, "Investigation of a nosocomial outbreak of severe acute respiratory syndrome(SARS)in Toronto, Canada", Cmaj, 169(4), pp.285~292 (2003)
  81. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virology journal, 2(1), pp.69~ (2005)
  82. WangC, "A novel coronavirus outbreak of global health concern", The Lancet, 395(10223), pp.470~473 (2020)
  83. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China", Jama, 323(11), pp.1061~1069 (2020)
  84. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell research, 30(3), pp.269~271 (2020)
  85. Wang Q-L, "Ginsenoside Rg1 regulatesSIRT1 to ameliorate sepsis-induced lung inflammation and injury via inhibiting endoplasmic reticulum stress and inflammation", Mediators of inflammation (2019)
  86. Wang W, "Updated understanding of the outbreak of 2019 novel coronavirus(2019-nCoV)in Wuhan, China", Journal of medical virology, 92(4), pp.441~447 (2020)
  87. Wang Y, "Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication", Antimicrobial agents and chemotherapy, 60(5), pp.2834~2848 (2016)
  88. Wu C-Y, "Small molecules targeting severe acute respiratory syndrome human coronavirus", Proceedings of the National Academy of Sciences, 101(27), pp.10012~10017 (2004)
  89. Wu X, "Melatonin alleviates radiation-induced lung injury via regulation of miR-30e", NLRP3 Axis, 2019, ~
  90. Yan Y, "Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model", Cell research, 23(2), pp.300~302 (2013)
  91. Yang Y, "Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China", MedRxiv, ~ (2020)
  92. Yip HK, "Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia–reperfusion injury", Journal of pineal research, 54(2), pp.207~221 (2013)
  93. Zheng BJ, "SARS-related virus predating SARS outbreak, Hong Kong", Emerging infectious diseases, 10(2), pp.176~ (2004)
  94. Zhou B, "Treatment with convalescent plasma for influenza A(H5N1)infection", New England Journal of Medicine, 357(14), pp.1450~1451 (2007)
  95. Zhu N, "A Novel Coronavirus from Patients with Pneumonia in China, 2019", N Engl J Med, 382(8), pp.727~733 (2020)
  96. Zumla A, "Coronaviruses-drug discovery and therapeutic options", Nature reviews Drug discovery, 15(5), pp.327~ (2016)

관련 논문AI추천

Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)김미화, 김범태, 김성준, 김해수, 명진종, 신혜진, 안대균, 이선희한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2020 · 제30권 제3호A Comprehensive Study of SARS-CoV-2: From 2019-nCoV to COVID-19 OutbreakAbdul Baset, Abdul Waris, Asmat Ali, Atta Ullah Khan, Muhammad Ali한국미생물·생명공학회 · 한국미생물·생명공학회지2020 · 제48권 제3호COVID-19: an update on diagnostic and therapeutic approachesAhmed Abdal Dayem, Balachandar Vellingiri, Kaavya Jayaramayya, Mahalaxmi Iyer, Mohana Devi Subramaniam, Soo Bin Lee, Ssang-Goo Cho생화학분자생물학회 · BMB Reports2020 · 제53권 제4호COVID-19 Antiviral and Treatment Candidates: Current Status김다정, 김정기, 김지연, 박성규, Españo Erica대한면역학회 · Immune Network2021 · 제21권 제1호Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19김두진, 이푸름대한면역학회 · Immune Network2020 · 제20권 제4호A Comprehensive Review of Coronavirus Disease 2019: Epidemiology, Transmission, Risk Factors, and International Responses범승원, 신재일, 이금화, 홍성휘, Ai Koyanagi, Andreas Kronbichler, Han Li, Lee Smith, Louis Jacob, Ramy Abou Ghayda연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제1호

이 간행물의 다른 논문 (7건)

Prevention of Eye Disorders through Healthy Lifestyle with special reference to PadabhyangaNeeru Nathani, Bijayashree Satapathypp. 18-18MANAGEMENT OF HASĀH WA RAML AL-KULYA (NEPHROLITHIASIS) IN UNANI SYSTEM OF MEDICINE: A REVIEWKhalid Ali Khan, Mohammad Zakir, Rashid Ali khanpp. 19-19A comprehensive review on Tukhm-e-Karafs (Apium graveolens L.) with special reference to Unani System of MedicineMohd Naushad, Mohammad Zakir, Munawwar Husain Kazmi, Najmus Saharpp. 20-20A Randomized Active Controlled Clinical Trial to Evaluate Safety and Efficacy of a Topical Unani Formulation Marham Kharish Jadeed in the Management of Qūbā (Tinea Corporis)M.H. Kazmi, Mohammad Nawab, Aaliya, Sana Ayyubpp. 22-22Clinical Effectiveness of a Unani Regimen in the Management of Hasāh al-kuliya (Nephrolithiasis): A Case ReportMohammad Nawab, Ifra Abdul Qaiyyumpp. 23-23
원문 보기